<!DOCTYPE html>
<html lang="en-US">
  <!-- Mirrored from bridgebio.com/news/bridgebio-announces-positive-phase-2-cohort-5-results-of-infigratinib-in-achondroplasia/ by HTTrack Website Copier/3.x [XR&CO'2014], Wed, 18 Dec 2024 11:00:25 GMT -->
  <!-- Added by HTTrack --><meta
    http-equiv="content-type"
    content="text/html;charset=UTF-8"
  /><!-- /Added by HTTrack -->
  <head>
    <title>Positive Phase 2 Cohort 5 Results of Infigratinib | BridgeBio</title>
    <meta charset="UTF-8" />
    <meta http-equiv="X-UA-Compatible" content="IE=edge" />
    <meta
      name="viewport"
      content="width=device-width, initial-scale=1, maximum-scale=5.0, minimum-scale=1"
    />
    <meta
      name="robots"
      content="index, follow, max-image-preview:large, max-snippet:-1, max-video-preview:-1"
    />

    <!-- This site is optimized with the Yoast SEO plugin v23.4 - https://yoast.com/wordpress/plugins/seo/ -->
    <meta
      name="description"
      content="BridgeBio announced positive results from PROPEL2 demonstrating potential best-in-class efficacy and a clean safety profile. Learn more today."
    />
    <link rel="canonical" href="index.html" />
    <meta property="og:locale" content="en_US" />
    <meta property="og:type" content="article" />
    <meta
      property="og:title"
      content="Positive Phase 2 Cohort 5 Results of Infigratinib | BridgeBio"
    />
    <meta
      property="og:description"
      content="BridgeBio announced positive results from PROPEL2 demonstrating potential best-in-class efficacy and a clean safety profile. Learn more today."
    />
    <meta property="og:url" content="index.html" />
    <meta property="og:site_name" content="BridgeBio" />
    <meta
      property="article:published_time"
      content="2023-03-06T12:00:47+00:00"
    />
    <meta
      property="article:modified_time"
      content="2023-06-13T19:50:39+00:00"
    />
    <meta
      property="og:image"
      content="../../wp-content/uploads/2019/02/BridgeBio_Share.png"
    />
    <meta property="og:image:width" content="1200" />
    <meta property="og:image:height" content="600" />
    <meta property="og:image:type" content="image/png" />
    <meta name="author" content="Holly Condon" />
    <meta name="twitter:card" content="summary_large_image" />
    <meta name="twitter:creator" content="@BridgeBioPharma" />
    <meta name="twitter:site" content="@BridgeBioPharma" />
    <meta name="twitter:label1" content="Written by" />
    <meta name="twitter:data1" content="Holly Condon" />
    <meta name="twitter:label2" content="Est. reading time" />
    <meta name="twitter:data2" content="8 minutes" />
    <script type="application/ld+json" class="yoast-schema-graph">
      {
        "@context": "https://schema.org",
        "@graph": [
          {
            "@type": "WebPage",
            "@id": "https://bridgebio.com/news/bridgebio-announces-positive-phase-2-cohort-5-results-of-infigratinib-in-achondroplasia/",
            "url": "https://bridgebio.com/news/bridgebio-announces-positive-phase-2-cohort-5-results-of-infigratinib-in-achondroplasia/",
            "name": "Positive Phase 2 Cohort 5 Results of Infigratinib | BridgeBio",
            "isPartOf": { "@id": "https://bridgebio.com/#website" },
            "datePublished": "2023-03-06T12:00:47+00:00",
            "dateModified": "2023-06-13T19:50:39+00:00",
            "author": {
              "@id": "https://bridgebio.com/#/schema/person/e56e9128cd840531b0acdca992cb1fca"
            },
            "description": "BridgeBio announced positive results from PROPEL2 demonstrating potential best-in-class efficacy and a clean safety profile. Learn more today.",
            "breadcrumb": {
              "@id": "https://bridgebio.com/news/bridgebio-announces-positive-phase-2-cohort-5-results-of-infigratinib-in-achondroplasia/#breadcrumb"
            },
            "inLanguage": "en-US",
            "potentialAction": [
              {
                "@type": "ReadAction",
                "target": [
                  "https://bridgebio.com/news/bridgebio-announces-positive-phase-2-cohort-5-results-of-infigratinib-in-achondroplasia/"
                ]
              }
            ]
          },
          {
            "@type": "BreadcrumbList",
            "@id": "https://bridgebio.com/news/bridgebio-announces-positive-phase-2-cohort-5-results-of-infigratinib-in-achondroplasia/#breadcrumb",
            "itemListElement": [
              {
                "@type": "ListItem",
                "position": 1,
                "name": "Home",
                "item": "https://bridgebio.com/"
              },
              {
                "@type": "ListItem",
                "position": 2,
                "name": "BridgeBio Announces Positive Phase 2 Cohort 5 Results of Infigratinib in Achondroplasia Demonstrating Mean Increase in Annualized Height Velocity of 3.03 cm/year with No Treatment-related Adverse Events"
              }
            ]
          },
          {
            "@type": "WebSite",
            "@id": "https://bridgebio.com/#website",
            "url": "https://bridgebio.com/",
            "name": "BridgeBio",
            "description": "",
            "potentialAction": [
              {
                "@type": "SearchAction",
                "target": {
                  "@type": "EntryPoint",
                  "urlTemplate": "https://bridgebio.com/?s={search_term_string}"
                },
                "query-input": {
                  "@type": "PropertyValueSpecification",
                  "valueRequired": true,
                  "valueName": "search_term_string"
                }
              }
            ],
            "inLanguage": "en-US"
          },
          {
            "@type": "Person",
            "@id": "https://bridgebio.com/#/schema/person/e56e9128cd840531b0acdca992cb1fca",
            "name": "Holly Condon",
            "image": {
              "@type": "ImageObject",
              "inLanguage": "en-US",
              "@id": "https://bridgebio.com/#/schema/person/image/",
              "url": "https://secure.gravatar.com/avatar/4465d7631588f41599cacc7a8380e613?s=96&d=mm&r=g",
              "contentUrl": "https://secure.gravatar.com/avatar/4465d7631588f41599cacc7a8380e613?s=96&d=mm&r=g",
              "caption": "Holly Condon"
            },
            "url": "https://bridgebio.com/author/hcondon/"
          }
        ]
      }
    </script>
    <!-- / Yoast SEO plugin. -->

    <link rel="dns-prefetch" href="http://cdnjs.cloudflare.com/" />
    <link rel="dns-prefetch" href="http://unpkg.com/" />
    <link rel="dns-prefetch" href="http://fonts.googleapis.com/" />
    <link
      rel="alternate"
      type="application/rss+xml"
      title="BridgeBio &raquo; BridgeBio Announces Positive Phase 2 Cohort 5 Results of Infigratinib in Achondroplasia Demonstrating Mean Increase in Annualized Height Velocity of 3.03 cm/year with No Treatment-related Adverse Events Comments Feed"
      href="feed/index.html"
    />
    <script type="text/javascript">
      /* <![CDATA[ */
      window._wpemojiSettings = {
        baseUrl: "https:\/\/s.w.org\/images\/core\/emoji\/15.0.3\/72x72\/",
        ext: ".png",
        svgUrl: "https:\/\/s.w.org\/images\/core\/emoji\/15.0.3\/svg\/",
        svgExt: ".svg",
        source: {
          concatemoji:
            "https:\/\/bridgebio.com\/wp-includes\/js\/wp-emoji-release.min.js?ver=6.6.2",
        },
      };
      /*! This file is auto-generated */
      !(function (i, n) {
        var o, s, e;
        function c(e) {
          try {
            var t = { supportTests: e, timestamp: new Date().valueOf() };
            sessionStorage.setItem(o, JSON.stringify(t));
          } catch (e) {}
        }
        function p(e, t, n) {
          e.clearRect(0, 0, e.canvas.width, e.canvas.height),
            e.fillText(t, 0, 0);
          var t = new Uint32Array(
              e.getImageData(0, 0, e.canvas.width, e.canvas.height).data
            ),
            r =
              (e.clearRect(0, 0, e.canvas.width, e.canvas.height),
              e.fillText(n, 0, 0),
              new Uint32Array(
                e.getImageData(0, 0, e.canvas.width, e.canvas.height).data
              ));
          return t.every(function (e, t) {
            return e === r[t];
          });
        }
        function u(e, t, n) {
          switch (t) {
            case "flag":
              return n(
                e,
                "\ud83c\udff3\ufe0f\u200d\u26a7\ufe0f",
                "\ud83c\udff3\ufe0f\u200b\u26a7\ufe0f"
              )
                ? !1
                : !n(
                    e,
                    "\ud83c\uddfa\ud83c\uddf3",
                    "\ud83c\uddfa\u200b\ud83c\uddf3"
                  ) &&
                    !n(
                      e,
                      "\ud83c\udff4\udb40\udc67\udb40\udc62\udb40\udc65\udb40\udc6e\udb40\udc67\udb40\udc7f",
                      "\ud83c\udff4\u200b\udb40\udc67\u200b\udb40\udc62\u200b\udb40\udc65\u200b\udb40\udc6e\u200b\udb40\udc67\u200b\udb40\udc7f"
                    );
            case "emoji":
              return !n(
                e,
                "\ud83d\udc26\u200d\u2b1b",
                "\ud83d\udc26\u200b\u2b1b"
              );
          }
          return !1;
        }
        function f(e, t, n) {
          var r =
              "undefined" != typeof WorkerGlobalScope &&
              self instanceof WorkerGlobalScope
                ? new OffscreenCanvas(300, 150)
                : i.createElement("canvas"),
            a = r.getContext("2d", { willReadFrequently: !0 }),
            o = ((a.textBaseline = "top"), (a.font = "600 32px Arial"), {});
          return (
            e.forEach(function (e) {
              o[e] = t(a, e, n);
            }),
            o
          );
        }
        function t(e) {
          var t = i.createElement("script");
          (t.src = e), (t.defer = !0), i.head.appendChild(t);
        }
        "undefined" != typeof Promise &&
          ((o = "wpEmojiSettingsSupports"),
          (s = ["flag", "emoji"]),
          (n.supports = { everything: !0, everythingExceptFlag: !0 }),
          (e = new Promise(function (e) {
            i.addEventListener("DOMContentLoaded", e, { once: !0 });
          })),
          new Promise(function (t) {
            var n = (function () {
              try {
                var e = JSON.parse(sessionStorage.getItem(o));
                if (
                  "object" == typeof e &&
                  "number" == typeof e.timestamp &&
                  new Date().valueOf() < e.timestamp + 604800 &&
                  "object" == typeof e.supportTests
                )
                  return e.supportTests;
              } catch (e) {}
              return null;
            })();
            if (!n) {
              if (
                "undefined" != typeof Worker &&
                "undefined" != typeof OffscreenCanvas &&
                "undefined" != typeof URL &&
                URL.createObjectURL &&
                "undefined" != typeof Blob
              )
                try {
                  var e =
                      "postMessage(" +
                      f.toString() +
                      "(" +
                      [JSON.stringify(s), u.toString(), p.toString()].join(
                        ","
                      ) +
                      "));",
                    r = new Blob([e], { type: "text/javascript" }),
                    a = new Worker(URL.createObjectURL(r), {
                      name: "wpTestEmojiSupports",
                    });
                  return void (a.onmessage = function (e) {
                    c((n = e.data)), a.terminate(), t(n);
                  });
                } catch (e) {}
              c((n = f(s, u, p)));
            }
            t(n);
          })
            .then(function (e) {
              for (var t in e)
                (n.supports[t] = e[t]),
                  (n.supports.everything =
                    n.supports.everything && n.supports[t]),
                  "flag" !== t &&
                    (n.supports.everythingExceptFlag =
                      n.supports.everythingExceptFlag && n.supports[t]);
              (n.supports.everythingExceptFlag =
                n.supports.everythingExceptFlag && !n.supports.flag),
                (n.DOMReady = !1),
                (n.readyCallback = function () {
                  n.DOMReady = !0;
                });
            })
            .then(function () {
              return e;
            })
            .then(function () {
              var e;
              n.supports.everything ||
                (n.readyCallback(),
                (e = n.source || {}).concatemoji
                  ? t(e.concatemoji)
                  : e.wpemoji && e.twemoji && (t(e.twemoji), t(e.wpemoji)));
            }));
      })((window, document), window._wpemojiSettings);
      /* ]]> */
    </script>
    <style id="wp-emoji-styles-inline-css" type="text/css">
      img.wp-smiley,
      img.emoji {
        display: inline !important;
        border: none !important;
        box-shadow: none !important;
        height: 1em !important;
        width: 1em !important;
        margin: 0 0.07em !important;
        vertical-align: -0.1em !important;
        background: none !important;
        padding: 0 !important;
      }
    </style>
    <style id="classic-theme-styles-inline-css" type="text/css">
      /*! This file is auto-generated */
      .wp-block-button__link {
        color: #fff;
        background-color: #32373c;
        border-radius: 9999px;
        box-shadow: none;
        text-decoration: none;
        padding: calc(0.667em + 2px) calc(1.333em + 2px);
        font-size: 1.125em;
      }
      .wp-block-file__button {
        background: #32373c;
        color: #fff;
        text-decoration: none;
      }
    </style>
    <style id="global-styles-inline-css" type="text/css">
      :root {
        --wp--preset--aspect-ratio--square: 1;
        --wp--preset--aspect-ratio--4-3: 4/3;
        --wp--preset--aspect-ratio--3-4: 3/4;
        --wp--preset--aspect-ratio--3-2: 3/2;
        --wp--preset--aspect-ratio--2-3: 2/3;
        --wp--preset--aspect-ratio--16-9: 16/9;
        --wp--preset--aspect-ratio--9-16: 9/16;
        --wp--preset--color--black: #000000;
        --wp--preset--color--cyan-bluish-gray: #abb8c3;
        --wp--preset--color--white: #ffffff;
        --wp--preset--color--pale-pink: #f78da7;
        --wp--preset--color--vivid-red: #cf2e2e;
        --wp--preset--color--luminous-vivid-orange: #ff6900;
        --wp--preset--color--luminous-vivid-amber: #fcb900;
        --wp--preset--color--light-green-cyan: #7bdcb5;
        --wp--preset--color--vivid-green-cyan: #00d084;
        --wp--preset--color--pale-cyan-blue: #8ed1fc;
        --wp--preset--color--vivid-cyan-blue: #0693e3;
        --wp--preset--color--vivid-purple: #9b51e0;
        --wp--preset--gradient--vivid-cyan-blue-to-vivid-purple: linear-gradient(
          135deg,
          rgba(6, 147, 227, 1) 0%,
          rgb(155, 81, 224) 100%
        );
        --wp--preset--gradient--light-green-cyan-to-vivid-green-cyan: linear-gradient(
          135deg,
          rgb(122, 220, 180) 0%,
          rgb(0, 208, 130) 100%
        );
        --wp--preset--gradient--luminous-vivid-amber-to-luminous-vivid-orange: linear-gradient(
          135deg,
          rgba(252, 185, 0, 1) 0%,
          rgba(255, 105, 0, 1) 100%
        );
        --wp--preset--gradient--luminous-vivid-orange-to-vivid-red: linear-gradient(
          135deg,
          rgba(255, 105, 0, 1) 0%,
          rgb(207, 46, 46) 100%
        );
        --wp--preset--gradient--very-light-gray-to-cyan-bluish-gray: linear-gradient(
          135deg,
          rgb(238, 238, 238) 0%,
          rgb(169, 184, 195) 100%
        );
        --wp--preset--gradient--cool-to-warm-spectrum: linear-gradient(
          135deg,
          rgb(74, 234, 220) 0%,
          rgb(151, 120, 209) 20%,
          rgb(207, 42, 186) 40%,
          rgb(238, 44, 130) 60%,
          rgb(251, 105, 98) 80%,
          rgb(254, 248, 76) 100%
        );
        --wp--preset--gradient--blush-light-purple: linear-gradient(
          135deg,
          rgb(255, 206, 236) 0%,
          rgb(152, 150, 240) 100%
        );
        --wp--preset--gradient--blush-bordeaux: linear-gradient(
          135deg,
          rgb(254, 205, 165) 0%,
          rgb(254, 45, 45) 50%,
          rgb(107, 0, 62) 100%
        );
        --wp--preset--gradient--luminous-dusk: linear-gradient(
          135deg,
          rgb(255, 203, 112) 0%,
          rgb(199, 81, 192) 50%,
          rgb(65, 88, 208) 100%
        );
        --wp--preset--gradient--pale-ocean: linear-gradient(
          135deg,
          rgb(255, 245, 203) 0%,
          rgb(182, 227, 212) 50%,
          rgb(51, 167, 181) 100%
        );
        --wp--preset--gradient--electric-grass: linear-gradient(
          135deg,
          rgb(202, 248, 128) 0%,
          rgb(113, 206, 126) 100%
        );
        --wp--preset--gradient--midnight: linear-gradient(
          135deg,
          rgb(2, 3, 129) 0%,
          rgb(40, 116, 252) 100%
        );
        --wp--preset--font-size--small: 13px;
        --wp--preset--font-size--medium: 20px;
        --wp--preset--font-size--large: 36px;
        --wp--preset--font-size--x-large: 42px;
        --wp--preset--spacing--20: 0.44rem;
        --wp--preset--spacing--30: 0.67rem;
        --wp--preset--spacing--40: 1rem;
        --wp--preset--spacing--50: 1.5rem;
        --wp--preset--spacing--60: 2.25rem;
        --wp--preset--spacing--70: 3.38rem;
        --wp--preset--spacing--80: 5.06rem;
        --wp--preset--shadow--natural: 6px 6px 9px rgba(0, 0, 0, 0.2);
        --wp--preset--shadow--deep: 12px 12px 50px rgba(0, 0, 0, 0.4);
        --wp--preset--shadow--sharp: 6px 6px 0px rgba(0, 0, 0, 0.2);
        --wp--preset--shadow--outlined: 6px 6px 0px -3px rgba(255, 255, 255, 1),
          6px 6px rgba(0, 0, 0, 1);
        --wp--preset--shadow--crisp: 6px 6px 0px rgba(0, 0, 0, 1);
      }
      :where(.is-layout-flex) {
        gap: 0.5em;
      }
      :where(.is-layout-grid) {
        gap: 0.5em;
      }
      body .is-layout-flex {
        display: flex;
      }
      .is-layout-flex {
        flex-wrap: wrap;
        align-items: center;
      }
      .is-layout-flex > :is(*, div) {
        margin: 0;
      }
      body .is-layout-grid {
        display: grid;
      }
      .is-layout-grid > :is(*, div) {
        margin: 0;
      }
      :where(.wp-block-columns.is-layout-flex) {
        gap: 2em;
      }
      :where(.wp-block-columns.is-layout-grid) {
        gap: 2em;
      }
      :where(.wp-block-post-template.is-layout-flex) {
        gap: 1.25em;
      }
      :where(.wp-block-post-template.is-layout-grid) {
        gap: 1.25em;
      }
      .has-black-color {
        color: var(--wp--preset--color--black) !important;
      }
      .has-cyan-bluish-gray-color {
        color: var(--wp--preset--color--cyan-bluish-gray) !important;
      }
      .has-white-color {
        color: var(--wp--preset--color--white) !important;
      }
      .has-pale-pink-color {
        color: var(--wp--preset--color--pale-pink) !important;
      }
      .has-vivid-red-color {
        color: var(--wp--preset--color--vivid-red) !important;
      }
      .has-luminous-vivid-orange-color {
        color: var(--wp--preset--color--luminous-vivid-orange) !important;
      }
      .has-luminous-vivid-amber-color {
        color: var(--wp--preset--color--luminous-vivid-amber) !important;
      }
      .has-light-green-cyan-color {
        color: var(--wp--preset--color--light-green-cyan) !important;
      }
      .has-vivid-green-cyan-color {
        color: var(--wp--preset--color--vivid-green-cyan) !important;
      }
      .has-pale-cyan-blue-color {
        color: var(--wp--preset--color--pale-cyan-blue) !important;
      }
      .has-vivid-cyan-blue-color {
        color: var(--wp--preset--color--vivid-cyan-blue) !important;
      }
      .has-vivid-purple-color {
        color: var(--wp--preset--color--vivid-purple) !important;
      }
      .has-black-background-color {
        background-color: var(--wp--preset--color--black) !important;
      }
      .has-cyan-bluish-gray-background-color {
        background-color: var(--wp--preset--color--cyan-bluish-gray) !important;
      }
      .has-white-background-color {
        background-color: var(--wp--preset--color--white) !important;
      }
      .has-pale-pink-background-color {
        background-color: var(--wp--preset--color--pale-pink) !important;
      }
      .has-vivid-red-background-color {
        background-color: var(--wp--preset--color--vivid-red) !important;
      }
      .has-luminous-vivid-orange-background-color {
        background-color: var(
          --wp--preset--color--luminous-vivid-orange
        ) !important;
      }
      .has-luminous-vivid-amber-background-color {
        background-color: var(
          --wp--preset--color--luminous-vivid-amber
        ) !important;
      }
      .has-light-green-cyan-background-color {
        background-color: var(--wp--preset--color--light-green-cyan) !important;
      }
      .has-vivid-green-cyan-background-color {
        background-color: var(--wp--preset--color--vivid-green-cyan) !important;
      }
      .has-pale-cyan-blue-background-color {
        background-color: var(--wp--preset--color--pale-cyan-blue) !important;
      }
      .has-vivid-cyan-blue-background-color {
        background-color: var(--wp--preset--color--vivid-cyan-blue) !important;
      }
      .has-vivid-purple-background-color {
        background-color: var(--wp--preset--color--vivid-purple) !important;
      }
      .has-black-border-color {
        border-color: var(--wp--preset--color--black) !important;
      }
      .has-cyan-bluish-gray-border-color {
        border-color: var(--wp--preset--color--cyan-bluish-gray) !important;
      }
      .has-white-border-color {
        border-color: var(--wp--preset--color--white) !important;
      }
      .has-pale-pink-border-color {
        border-color: var(--wp--preset--color--pale-pink) !important;
      }
      .has-vivid-red-border-color {
        border-color: var(--wp--preset--color--vivid-red) !important;
      }
      .has-luminous-vivid-orange-border-color {
        border-color: var(
          --wp--preset--color--luminous-vivid-orange
        ) !important;
      }
      .has-luminous-vivid-amber-border-color {
        border-color: var(--wp--preset--color--luminous-vivid-amber) !important;
      }
      .has-light-green-cyan-border-color {
        border-color: var(--wp--preset--color--light-green-cyan) !important;
      }
      .has-vivid-green-cyan-border-color {
        border-color: var(--wp--preset--color--vivid-green-cyan) !important;
      }
      .has-pale-cyan-blue-border-color {
        border-color: var(--wp--preset--color--pale-cyan-blue) !important;
      }
      .has-vivid-cyan-blue-border-color {
        border-color: var(--wp--preset--color--vivid-cyan-blue) !important;
      }
      .has-vivid-purple-border-color {
        border-color: var(--wp--preset--color--vivid-purple) !important;
      }
      .has-vivid-cyan-blue-to-vivid-purple-gradient-background {
        background: var(
          --wp--preset--gradient--vivid-cyan-blue-to-vivid-purple
        ) !important;
      }
      .has-light-green-cyan-to-vivid-green-cyan-gradient-background {
        background: var(
          --wp--preset--gradient--light-green-cyan-to-vivid-green-cyan
        ) !important;
      }
      .has-luminous-vivid-amber-to-luminous-vivid-orange-gradient-background {
        background: var(
          --wp--preset--gradient--luminous-vivid-amber-to-luminous-vivid-orange
        ) !important;
      }
      .has-luminous-vivid-orange-to-vivid-red-gradient-background {
        background: var(
          --wp--preset--gradient--luminous-vivid-orange-to-vivid-red
        ) !important;
      }
      .has-very-light-gray-to-cyan-bluish-gray-gradient-background {
        background: var(
          --wp--preset--gradient--very-light-gray-to-cyan-bluish-gray
        ) !important;
      }
      .has-cool-to-warm-spectrum-gradient-background {
        background: var(
          --wp--preset--gradient--cool-to-warm-spectrum
        ) !important;
      }
      .has-blush-light-purple-gradient-background {
        background: var(--wp--preset--gradient--blush-light-purple) !important;
      }
      .has-blush-bordeaux-gradient-background {
        background: var(--wp--preset--gradient--blush-bordeaux) !important;
      }
      .has-luminous-dusk-gradient-background {
        background: var(--wp--preset--gradient--luminous-dusk) !important;
      }
      .has-pale-ocean-gradient-background {
        background: var(--wp--preset--gradient--pale-ocean) !important;
      }
      .has-electric-grass-gradient-background {
        background: var(--wp--preset--gradient--electric-grass) !important;
      }
      .has-midnight-gradient-background {
        background: var(--wp--preset--gradient--midnight) !important;
      }
      .has-small-font-size {
        font-size: var(--wp--preset--font-size--small) !important;
      }
      .has-medium-font-size {
        font-size: var(--wp--preset--font-size--medium) !important;
      }
      .has-large-font-size {
        font-size: var(--wp--preset--font-size--large) !important;
      }
      .has-x-large-font-size {
        font-size: var(--wp--preset--font-size--x-large) !important;
      }
      :where(.wp-block-post-template.is-layout-flex) {
        gap: 1.25em;
      }
      :where(.wp-block-post-template.is-layout-grid) {
        gap: 1.25em;
      }
      :where(.wp-block-columns.is-layout-flex) {
        gap: 2em;
      }
      :where(.wp-block-columns.is-layout-grid) {
        gap: 2em;
      }
      :root :where(.wp-block-pullquote) {
        font-size: 1.5em;
        line-height: 1.6;
      }
    </style>
    <link
      rel="stylesheet"
      id="google-fonts-css"
      href="https://fonts.googleapis.com/css2?family=Source+Sans+Pro:wght@300;400;700&amp;display=swap"
      type="text/css"
      media="all"
    />
    <link
      rel="stylesheet"
      id="slick-css-css"
      href="../../../cdnjs.cloudflare.com/ajax/libs/slick-carousel/1.8.1/slick109c.css?ver=6.6.2"
      type="text/css"
      media="all"
    />
    <link
      rel="stylesheet"
      id="aos-css-css"
      href="../../../unpkg.com/aos%403.0.0-beta.6/dist/aos.css?ver=6.6.2"
      type="text/css"
      media="all"
    />
    <link
      rel="stylesheet"
      id="main-styles-css"
      href="../../wp-content/themes/bridgebio/style3779.css?ver=1734511320"
      type="text/css"
      media="all"
    />
    <link
      rel="stylesheet"
      id="secondary-styles-css"
      href="../../wp-content/themes/bridgebio/assets/css/secondary-css3779.css?ver=1734511320"
      type="text/css"
      media="all"
    />
    <link
      rel="stylesheet"
      id="onetrust-css"
      href="../../wp-content/themes/bridgebio/assets/css/onetrust3779.css?ver=1734511320"
      type="text/css"
      media="all"
    />
    <script
      type="text/javascript"
      src="../../wp-includes/js/jquery/jquery.minf43b.js?ver=3.7.1"
      id="jquery-core-js"
    ></script>
    <script
      type="text/javascript"
      src="../../wp-includes/js/jquery/jquery-migrate.min5589.js?ver=3.4.1"
      id="jquery-migrate-js"
    ></script>
    <script
      type="text/javascript"
      src="../../wp-content/themes/bridgebio/assets/js/scripts3779.js?ver=1734511320"
      id="theme-scripts-js"
    ></script>
    <script
      type="text/javascript"
      src="../../../cdnjs.cloudflare.com/ajax/libs/slick-carousel/1.8.1/slick109c.js?ver=6.6.2"
      id="slick-scripts-js"
    ></script>
    <script
      type="text/javascript"
      src="../../../unpkg.com/aos%403.0.0-beta.6/dist/aos.js?ver=6.6.2"
      id="aos-scripts-js"
    ></script>
    <script
      type="text/javascript"
      src="../../wp-content/themes/bridgebio/assets/js/modal3779.js?ver=1734511320"
      id="modal-js"
    ></script>
    <link rel="https://api.w.org/" href="../../wp-json/index.html" />
    <link
      rel="alternate"
      title="JSON"
      type="application/json"
      href="../../wp-json/wp/v2/posts/5841.json"
    />
    <link
      rel="EditURI"
      type="application/rsd+xml"
      title="RSD"
      href="../../xmlrpc0db0.php?rsd"
    />
    <link rel="shortlink" href="../../index19ea.html?p=5841" />
    <link
      rel="alternate"
      title="oEmbed (JSON)"
      type="application/json+oembed"
      href="../../wp-json/oembed/1.0/embed5dce.json?url=https%3A%2F%2Fbridgebio.com%2Fnews%2Fbridgebio-announces-positive-phase-2-cohort-5-results-of-infigratinib-in-achondroplasia%2F"
    />
    <link
      rel="alternate"
      title="oEmbed (XML)"
      type="text/xml+oembed"
      href="../../wp-json/oembed/1.0/embedf707?url=https%3A%2F%2Fbridgebio.com%2Fnews%2Fbridgebio-announces-positive-phase-2-cohort-5-results-of-infigratinib-in-achondroplasia%2F&amp;format=xml"
    />
    <link
      rel="icon"
      href="../../wp-content/uploads/2024/02/cropped-cropped-favicon-32x32.png"
      sizes="32x32"
    />
    <link
      rel="icon"
      href="../../wp-content/uploads/2024/02/cropped-cropped-favicon-192x192.png"
      sizes="192x192"
    />
    <link
      rel="apple-touch-icon"
      href="../../wp-content/uploads/2024/02/cropped-cropped-favicon-180x180.png"
    />
    <meta
      name="msapplication-TileImage"
      content="https://bridgebio.com/wp-content/uploads/2024/02/cropped-cropped-favicon-270x270.png"
    />
    <!-- OneTrust Cookies Consent Notice start for www.bridgebio.com -->
    <script
      src="../../../cdn.cookielaw.org/scripttemplates/otSDKStub.js"
      type="text/javascript"
      charset="UTF-8"
      data-domain-script="0191509e-107d-7797-bc76-f2cb533e79d3"
    ></script>
    <script type="text/javascript">
      function OptanonWrapper() {}
    </script>
    <!-- End OneTrust -->
    <!-- Google Tag Manager -->
    <script>
      (function (w, d, s, l, i) {
        w[l] = w[l] || [];
        w[l].push({ "gtm.start": new Date().getTime(), event: "gtm.js" });
        var f = d.getElementsByTagName(s)[0],
          j = d.createElement(s),
          dl = l != "dataLayer" ? "&l=" + l : "";
        j.async = true;
        j.src = "../../../www.googletagmanager.com/gtm5445.html?id=" + i + dl;
        f.parentNode.insertBefore(j, f);
      })(window, document, "script", "dataLayer", "GTM-T94V2KL");
    </script>
    <!-- End Google Tag Manager -->
    <!-- Marker.io Script -->
    <script>
      window.markerConfig = {
        project: "66622db13004831ec32eb666",
        source: "snippet",
      };
      !(function (e, r, a) {
        if (!e.__Marker) {
          e.__Marker = {};
          var t = [],
            n = { __cs: t };
          [
            "show",
            "hide",
            "isVisible",
            "capture",
            "cancelCapture",
            "unload",
            "reload",
            "isExtensionInstalled",
            "setReporter",
            "setCustomData",
            "on",
            "off",
          ].forEach(function (e) {
            n[e] = function () {
              var r = Array.prototype.slice.call(arguments);
              r.unshift(e), t.push(r);
            };
          }),
            (e.Marker = n);
          var s = r.createElement("script");
          (s.async = 1), (s.src = "../../../edge.marker.io/latest/shim.js");
          var i = r.getElementsByTagName("script")[0];
          i.parentNode.insertBefore(s, i);
        }
      })(window, document);
    </script>
    <!-- End Marker.io Script -->
  </head>

  <body
    class="post-template-default single single-post postid-5841 single-format-standard"
  >
    <!-- Google Tag Manager (noscript) -->
    <noscript
      ><iframe
        src="https://www.googletagmanager.com/ns.html?id=GTM-T94V2KL"
        height="0"
        width="0"
        style="display: none; visibility: hidden"
      ></iframe
    ></noscript>
    <!-- End Google Tag Manager (noscript) -->

    <nav
      class="nav nav--secondary nav--dark"
      style="--navbar-bg-color: transparent; position: relative"
    >
      <div class="nav--bg-color"></div>
      <div class="nav__content-wrapper">
        <div class="nav__menu-takeover"></div>
        <div class="nav__logo-container">
          <a href="../../index.html" class="" data-ol-has-click-handler="">
            <img
              src="../../bridge logo.webp"
              class="nav__logo hide-me"
              alt="BridgeBio logo"
            />
            <img
              src="../../bridge logo.webp"
              class="nav__logo"
              alt="BridgeBio logo"
            />
          </a>
        </div>
        <ul class="nav__menu">
          <li
            id="menu-item-4126"
            class="menu-item menu-item-type-post_type menu-item-object-page menu-item-has-children menu-item-4126"
          >
            <a href="../../about-us/index.html">about us</a>
            <ul class="sub-menu">
              <li
                id="menu-item-6716"
                class="menu-item menu-item-type-custom menu-item-object-custom menu-item-6716"
              >
                <a href="../../about-us/index.html">overview</a>
              </li>
              <li
                id="menu-item-4093"
                class="menu-item menu-item-type-post_type menu-item-object-page menu-item-4093"
              >
                <a href="../../people/index.html">people</a>
              </li>
              <li
                id="menu-item-5080"
                class="menu-item menu-item-type-post_type menu-item-object-page menu-item-5080"
              >
                <a href="../../partners/index.html">partners</a>
              </li>
              <li
                id="menu-item-4159"
                class="menu-item menu-item-type-post_type menu-item-object-page menu-item-4159"
              >
                <a href="../../careers/index.html">careers</a>
              </li>
            </ul>
          </li>
          <li
            id="menu-item-6309"
            class="menu-item menu-item-type-post_type menu-item-object-page menu-item-has-children menu-item-6309"
          >
            <a href="../../pipeline/index.html">science &#038; pipeline</a>
            <ul class="sub-menu">
              <li
                id="menu-item-6302"
                class="menu-item menu-item-type-custom menu-item-object-custom menu-item-6302"
              >
                <a href="../../pipeline/index.html#pipeline">pipeline</a>
              </li>
              <li
                id="menu-item-6306"
                class="menu-item menu-item-type-post_type menu-item-object-page menu-item-6306"
              >
                <a href="../../publications/index.html">publications</a>
              </li>
              <li
                id="menu-item-6315"
                class="menu-item menu-item-type-post_type menu-item-object-page menu-item-6315"
              >
                <a href="../../licensing-opportunities.html"
                  >licensing opportunities</a
                >
              </li>
            </ul>
          </li>
          <li
            id="menu-item-6848"
            class="menu-item menu-item-type-custom menu-item-object-custom menu-item-has-children menu-item-6848"
          >
            <a href="#">products</a>
            <ul class="sub-menu">
              <li
                id="menu-item-7104"
                class="menu-item menu-item-type-custom menu-item-object-custom menu-item-7104"
              >
                <a
                  target="_blank"
                  rel="noopener"
                  href="https://www.attruby.com/"
                  >Attruby</a
                >
              </li>
              <li
                id="menu-item-6852"
                class="menu-item menu-item-type-custom menu-item-object-custom menu-item-6852"
              >
                <a target="_blank" rel="noopener" href="https://nulibry.com/"
                  >Nulibry</a
                >
              </li>
            </ul>
          </li>
          <li
            id="menu-item-4316"
            class="menu-item menu-item-type-post_type menu-item-object-page menu-item-has-children menu-item-4316"
          >
            <a href="../../patients-and-families/index.html"
              >patients &#038; families</a
            >
            <ul class="sub-menu">
              <li
                id="menu-item-7043"
                class="menu-item menu-item-type-custom menu-item-object-custom menu-item-7043"
              >
                <a href="../../patients-and-families/alexis/index.html"
                  >Alexis’ story</a
                >
              </li>
              <li
                id="menu-item-7044"
                class="menu-item menu-item-type-custom menu-item-object-custom menu-item-7044"
              >
                <a href="../../patients-and-families/elliott/index.html"
                  >Elliott’s story</a
                >
              </li>
              <li
                id="menu-item-7045"
                class="menu-item menu-item-type-custom menu-item-object-custom menu-item-7045"
              >
                <a href="../../patients-and-families/miguel/index.html"
                  >Miguel’s story</a
                >
              </li>
              <li
                id="menu-item-7046"
                class="menu-item menu-item-type-custom menu-item-object-custom menu-item-7046"
              >
                <a href="../../patients-and-families/tobin/index.html"
                  >Tobin’s story</a
                >
              </li>
            </ul>
          </li>
          <li
            id="menu-item-6296"
            class="menu-item menu-item-type-custom menu-item-object-custom menu-item-has-children menu-item-6296"
          >
            <a href="https://investor.bridgebio.com/">for investors</a>
            <ul class="sub-menu">
              <li
                id="menu-item-6297"
                class="menu-item menu-item-type-custom menu-item-object-custom menu-item-6297"
              >
                <a href="https://investor.bridgebio.com/press-releases"
                  >press releases</a
                >
              </li>
              <li
                id="menu-item-6298"
                class="menu-item menu-item-type-custom menu-item-object-custom menu-item-6298"
              >
                <a
                  href="https://investor.bridgebio.com/news-and-events/event-calendar"
                  >events</a
                >
              </li>
              <li
                id="menu-item-6303"
                class="menu-item menu-item-type-custom menu-item-object-custom menu-item-6303"
              >
                <a href="https://investor.bridgebio.com/presentations"
                  >presentations</a
                >
              </li>
              <li
                id="menu-item-6299"
                class="menu-item menu-item-type-custom menu-item-object-custom menu-item-6299"
              >
                <a
                  href="https://investor.bridgebio.com/financials-and-filings/sec-filings"
                  >SEC filings</a
                >
              </li>
              <li
                id="menu-item-6300"
                class="menu-item menu-item-type-custom menu-item-object-custom menu-item-6300"
              >
                <a href="https://investor.bridgebio.com/corporate-governance"
                  >corporate governance</a
                >
              </li>
              <li
                id="menu-item-6301"
                class="menu-item menu-item-type-custom menu-item-object-custom menu-item-6301"
              >
                <a
                  href="https://investor.bridgebio.com/stock-information/analyst-coverage"
                  >analyst coverage</a
                >
              </li>
            </ul>
          </li>
          <li
            id="menu-item-6295"
            class="menu-item menu-item-type-post_type menu-item-object-page menu-item-6295"
          >
            <a href="../index.html">news</a>
          </li>
        </ul>
        <button class="nav__toggle-button" data-ol-has-click-handler="">
          <div id="hamburger"><span></span><span></span><span></span></div>
          <div id="cross"><span></span><span></span></div>
        </button>
      </div>
    </nav>
    <main class="news-detail">
      <div class="flex-row">
        <div class="flex-column two-three">
          <article class="news-detail__post-content">
            <h1 class="page__title titlecase">
              BridgeBio Announces Positive Phase 2 Cohort 5 Results of
              Infigratinib in Achondroplasia Demonstrating Mean Increase in
              Annualized Height Velocity of 3.03 cm/year with No
              Treatment-related Adverse Events
            </h1>
            <section>
              <p align="center">
                <em
                  >&#8211; In the highest dose level (Cohort 5, 0.25 mg/kg once
                  daily), the mean change from baseline in annualized height
                  velocity (AHV) at six months was +3.03 cm/yr (p = 0.0022</em
                ><em
                  >) for the first 10 children with at least six months of
                  follow-up in Cohort 5. The two remaining children who have not
                  yet had six months of follow-up have a mean change from
                  baseline in AHV of </em
                ><em>+8.8 cm/yr based on three months data</em>
              </p>
              <p align="center">
                <em
                  >&#8211; 80% of children at six months were responders, as
                  defined by an increase from baseline AHV of at least 25%. The
                  mean change from baseline in AHV of responders was 3.81
                  cm/yr</em
                >
              </p>
              <p align="center">
                <em
                  >&#8211; As a result of treatment, the median absolute AHV
                  reached 7.6 cm/yr, which is beyond the 99th percentile of
                  growth for children living with achondroplasia</em
                >
              </p>
              <p align="center">
                <em
                  >&#8211; Infigratinib demonstrated clear dose-responsiveness
                  as a single daily oral therapy and was well-tolerated with no
                  adverse events (AEs) assessed as treatment-related in Cohort
                  5</em
                >
              </p>
              <p align="center">
                <em
                  >&#8211; Based on the positive Phase 2 results, BridgeBio has
                  started to enroll children for a pivotal Phase 3 trial</em
                >
              </p>
              <p align="center">
                <em
                  >&#8211; BridgeBio expects to initiate clinical development of
                  infigratinib for hypochondroplasia, a skeletal dysplasia
                  closely related to achondroplasia and driven by fibroblast
                  growth factor receptor 3 (FGFR3) gain-of-function variants,
                  and will continue to explore the impact on the medical and
                  functional complications of achondroplasia in future studies
                  of infigratinib</em
                >
              </p>
              <p>
                <strong
                  >PALO ALTO, Calif., March 06, 2023 (GLOBE NEWSWIRE)</strong
                >
                &#8212; BridgeBio Pharma, Inc. (Nasdaq: BBIO) (BridgeBio), a
                commercial-stage biopharmaceutical company focused on genetic
                diseases and cancers, today announced positive results from
                PROPEL2, a Phase 2 trial of the investigational therapy
                infigratinib in children with achondroplasia, demonstrating
                potential best-in-class efficacy and a clean safety profile.
                Infigratinib is an oral small molecule designed to inhibit FGFR3
                and target achondroplasia at its source. BridgeBio will also
                host an investor call on March 6, 2023, at 7:30 am ET to discuss
                the results from the Phase 2 study.
              </p>
              <p>To date, key results from the clinical trial include:</p>
              <ul type="disc">
                <li>
                  At the highest dose level evaluated to date (Cohort 5, 0.25
                  mg/kg once daily), the mean increase from baseline in
                  annualized height velocity (AHV) for the 10 children that have
                  had six-month visits was +3.03 cm/yr (p = 0.0022). Individual
                  data can be found in Figure 1 below
                </li>
                <li>
                  The baseline AHV for the 10 children with six-month visits was
                  in the expected range for children with achondroplasia at 3.73
                  cm/yr, rising to 6.77 cm/yr after treatment
                </li>
                <li>
                  The two remaining children who have not yet had six months of
                  follow-up have a mean change from baseline in AHV of +8.8
                  cm/yr at three months. The mean age for the cohort was 7.24
                  years
                </li>
                <li>
                  80% of the 10 children with six-month visits were responders,
                  with a change from baseline AHV of at least 25%. Among the
                  responders, the average change from baseline in AHV was +3.81
                  cm/yr
                </li>
                <li>
                  Preliminary analysis of Collagen X (CXM) levels also saw a
                  statistically significant increase from baseline in Cohort 5
                  (p=.03). CXM is the gold-standard biomarker of
                  chondrocyte-driven growth and further validates the robust
                  response to infigratinib
                </li>
                <li>
                  Combined with the previously reported Cohort 4 change from
                  baseline in AHV value of +1.52 cm/yr, the Cohort 5 data
                  demonstrate a strong dose response for infigratinib
                </li>
                <li>
                  Median follow-up across all cohorts is 71.1 weeks. To date,
                  the study has shown a well-tolerated safety profile, with no
                  study drug related treatment emergent adverse events (TEAEs)
                  in Cohort 5. No serious adverse events (SAEs) or
                  discontinuations due to AEs were reported in any cohort
                </li>
              </ul>
              <p><strong>Figure 1</strong></p>
              <p>
                <img
                  fetchpriority="high"
                  decoding="async"
                  class="hugin aligncenter"
                  src="data:image/jpeg;base64,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"
                  alt="Individual absolute AHV data for Cohort 5 participants"
                  width="599"
                  height="262"
                  name="GNW_RichHtml_External_IMG"
                />
              </p>
              <p>
                “The data from Cohort 5 has shown a major impact on annualized
                height velocity for children with achondroplasia and an
                excellent safety profile to date. We are thrilled to see these
                promising results and consider that AHV increases of this
                magnitude will translate to improvements in the medical and
                functional complications of achondroplasia. We are excited about
                taking the next steps towards initiating a Phase 3, pivotal
                clinical trial,” said Professor Ravi Savarirayan, M.D., Ph.D.,
                clinical geneticist and group leader of molecular therapies
                research at the Murdoch Children’s Research Institute in
                Australia, the lead investigator for PROPEL2.
              </p>
              <p>
                “I am encouraged by these efficacy and safety results and
                thankful for our partnership with the physicians, community
                advocates, children, and families in this study. These results
                reach a new tier of efficacy, and coupled with our
                differentiated safety and convenience profile, provide us the
                opportunity to serve children with achondroplasia and other
                skeletal dysplasias. We look forward to exploring the potential
                of infigratinib on the wider medical and functional impacts of
                achondroplasia, hypochondroplasia and other skeletal dysplasias,
                which hold significant unmet needs for families,” said Neil
                Kumar, Ph.D., founder and CEO of BridgeBio.
              </p>
              <p>
                Based on the positive results to date, BridgeBio has started
                enrolling children in the run-in for a Phase 3 trial.
                Additionally, BridgeBio expects to initiate clinical development
                for infigratinib in hypochondroplasia, a skeletal dysplasia
                closely related to achondroplasia and similarly driven by FGFR3
                gain-of-function variants. BridgeBio has previously presented
                promising preclinical data for hypochondroplasia at ENDO 2022
                and ASHG 2022.
              </p>
              <p>
                “Achondroplasia can have broad impact that affects the whole
                person. People can experience a range of medical complications,
                including foramen magnum stenosis, spinal stenosis,
                cardiovascular complications, sleep-disordered breathing,
                obesity, and sometimes, individuals may need surgical
                intervention. In addition to the potential medical and physical
                complications, people with achondroplasia may also experience
                social and emotional impacts as a result of living with the
                condition. We are encouraged by BridgeBio’s mission to develop a
                therapy with the potential to address this as a whole-person
                condition that affects the overall health, independent function,
                and quality of life of those with achondroplasia,” said Dianne
                Kremidas, executive director of The MAGIC Foundation.
              </p>
              <p>Infigratinib has IP protection out to at least 2041.</p>
              <p>
                <strong>Webcast Information</strong><br />
                BridgeBio will host an investor call and simultaneous webcast to
                discuss the Phase 2 data from Cohort 5 of infigratinib in
                children with achondroplasia on March 6, 2023 at 7:30 am ET. A
                link to the webcast may be accessed from the event calendar page
                of BridgeBio’s website at <a
                  href="https://investor.bridgebiodev.wpengine.com/"
                  target="_blank"
                  rel="nofollow noopener"
                  >https://investor.bridgebiodev.wpengine.com/</a
                >. A replay of the conference call and webcast will be archived
                on the Company’s website and will be available for at least 30
                days following the event.
              </p>
              <p>
                <strong>About Achondroplasia</strong><br />
                Achondroplasia is the most common cause of disproportionate
                short stature, affecting approximately 55,000 people in the
                United States (US) and European Union (EU), including up to
                10,000 children and adolescents with open growth plates.
                Achondroplasia impacts overall health and quality of life,
                leading to medical complications such as obstructive sleep
                apnea, middle ear dysfunction, kyphosis, and spinal stenosis.
                The condition is uniformly caused by an activating mutation in
                FGFR3.
              </p>
              <p>
                <strong>About BridgeBio Pharma, Inc.</strong><br />
                BridgeBio Pharma (BridgeBio) is a commercial-stage
                biopharmaceutical company founded to discover, create, test and
                deliver transformative medicines to treat patients who suffer
                from genetic diseases and cancers with clear genetic drivers.
                BridgeBio’s pipeline of development programs ranges from early
                science to advanced clinical trials. BridgeBio was founded in
                2015 and its team of experienced drug discoverers, developers
                and innovators are committed to applying advances in genetic
                medicine to help patients as quickly as possible. For more
                information visit <a
                  href="../../index.html"
                  target="_blank"
                  rel="nofollow noopener"
                  ><strong>bridgebiodev.wpengine.com</strong></a
                > and follow us on <a
                  href="https://www.linkedin.com/company/bridgebio/"
                  target="_blank"
                  rel="nofollow noopener"
                  ><strong>LinkedIn</strong></a
                > and <a
                  href="https://twitter.com/BridgeBioPharma"
                  target="_blank"
                  rel="nofollow noopener"
                  ><strong>Twitter</strong></a
                >.
              </p>
              <p>
                <strong
                  >BridgeBio Pharma, Inc. Forward-Looking Statements</strong
                ><br />
                This press release contains forward-looking statements.
                Statements in this press release may include statements that are
                not historical facts and are considered forward-looking within
                the meaning of Section 27A of the Securities Act of 1933, as
                amended (the Securities Act), and Section 21E of the Securities
                Exchange Act of 1934, as amended (the Exchange Act), which are
                usually identified by the use of words such as “anticipates,”
                “believes,” “estimates,” “expects,” “intends,” “may,” “plans,”
                “projects,” “seeks,” “should,” “will,” and variations of such
                words or similar expressions. We intend these forward-looking
                statements to be covered by the safe harbor provisions for
                forward-looking statements contained in Section 27A of the
                Securities Act and Section 21E of the Exchange Act. These
                forward-looking statements, including statements relating to the
                clinical, therapeutic and market potential of our programs and
                product candidates, including our clinical development program
                for infigratinib in achondroplasia, the timing and success of
                our clinical development programs, the progress of our ongoing
                and planned clinical trials of infigratinib in achondroplasia
                and in hypochondroplasia, including our plans to initiate a
                Phase 3 trial for infigratinib in achondroplasia and to initiate
                clinical development in hypochondroplasia, our planned
                interactions with regulatory authorities, the availability of
                data from our clinical trials of infigratinib, and the timing of
                these events, reflect our current views about our plans,
                intentions, expectations and strategies, which are based on the
                information currently available to us and on assumptions we have
                made. Although we believe that our plans, intentions,
                expectations and strategies as reflected in or suggested by
                those forward-looking statements are reasonable, we can give no
                assurance that the plans, intentions, expectations or strategies
                will be attained or achieved. Furthermore, actual results may
                differ materially from those described in the forward-looking
                statements and will be affected by a number of risks,
                uncertainties and assumptions, including, but not limited to,
                initial and ongoing data from our clinical trials not being
                indicative of final data, the design and success of ongoing and
                planned clinical trials, difficulties with enrollment in our
                clinical trials, adverse events that may be encountered in our
                clinical trials, the FDA or other regulatory agencies not
                agreeing with our regulatory approval strategies, components of
                our filings, such as clinical trial designs, conduct and
                methodologies, or the sufficiency of data submitted, potential
                adverse impacts due to the global COVID-19 pandemic such as
                delays in regulatory review, manufacturing and supply chain
                interruptions, adverse effects on healthcare systems and
                disruption of the global economy, the impacts of current
                macroeconomic and geopolitical events, including changing
                conditions from the COVID-19 pandemic, hostilities in Ukraine,
                increasing rates of inflation and rising interest rates, on our
                overall business operations and expectations, as well as those
                risks set forth in the Risk Factors section of our Annual Report
                on Form 10-K for the year ended December 31, 2022 and our other
                filings with the U.S. Securities and Exchange Commission.
                Moreover, we operate in a very competitive and rapidly changing
                environment in which new risks emerge from time to time. These
                forward-looking statements are based upon the current
                expectations and beliefs of our management as of the date of
                this press release, and are subject to certain risks and
                uncertainties that could cause actual results to differ
                materially from those described in the forward-looking
                statements. Except as required by applicable law, we assume no
                obligation to update publicly any forward-looking statements,
                whether as a result of new information, future events or
                otherwise.
              </p>
              <p>
                <strong>BridgeBio Contact:</strong><br />
                Vikram Bali<br />
                <a
                  href="https://www.globenewswire.com/Tracker?data=fugVVwAx1GYYTInBeTohYDy4FLEcn5zgfziCScXYuDM_iXkWjOkg3QygLNq5Q7gd5LneNVpma5M7gKAxmAefYpFajTkwnRTdm371CnV3i-E="
                  target="_blank"
                  rel="nofollow noopener"
                  ><span
                    class="__cf_email__"
                    data-cfemail="66050908120705122604140f020103040f090203104811160308010f08034805090b"
                    >[email&#160;protected]</span
                  ></a
                ><a
                  href="https://www.globenewswire.com/Tracker?data=fugVVwAx1GYYTInBeTohYDy4FLEcn5zgfziCScXYuDM_iXkWjOkg3QygLNq5Q7gd5LneNVpma5M7gKAxmAefYpFajTkwnRTdm371CnV3i-E="
                  target="_blank"
                  rel="nofollow noopener"
                  ><br /> </a
                >(650)-789-8220
              </p>
              <p>
                <strong>BridgeBio Skeletal Dysplasia Advocacy Contact:</strong
                ><br />
                Anne Lee<br />
                <a
                  href="../../cdn-cgi/l/email-protection.html#43222d2d266d2f26260321312a272426212a2c2726356d3433262d242a2d266d202c2e"
                  target="_blank"
                  rel="nofollow noopener"
                  ><span
                    class="__cf_email__"
                    data-cfemail="0e4f60606b20426b6b4e6c7c676a696b6c67616a6b7820797e6b606967606b206d6163"
                    >[email&#160;protected]</span
                  ></a
                ><br />
                (415)-694-0979
              </p>
              <p>&nbsp;</p>
            </section>
          </article>
        </div>
        <div class="flex-column one-three listing no-cap">
          <header class="intro">
            <h4><a href="../index.html" class="red uppercase">News</a></h4>
            <small class="date">03.06.2023</small>
            <hr />
            <p>
              <em>Hope through rigorous science</em> - medicines with
              transformative potential for patients with unmet needs.
            </p>
            <p>
              <a href="../../about-us/index.html" class="button">Our Mission</a>
            </p>
          </header>
        </div>
      </div>
    </main>

    <footer class="footer">
      <div class="content-form text-center">
        <h2>join our mailing list</h2>
        <p class="stay-informed">
          Stay informed on everything that is happening at BridgeBio.
        </p>
        <button
          type="button"
          class="button sign-up-button button--secondary-blue"
        >
          <span>SIGN UP</span>
          <img
            src="../../wp-content/themes/bridgebio/assets/img/icons/chevron-down-light.svg"
            width="24px"
            alt=""
          />
        </button>
        <div class="content-form">
          <p class="thank-you-message">Thanks for submitting the form.</p>
          <script
            data-cfasync="false"
            src="../../cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"
          ></script>
          <script src="../../../pages.bridgebio.com/js/forms2/js/forms2.min.js"></script>
          <form id="mktoForm_8"></form>
          <script>
            MktoForms2.loadForm(
              "//pages.bridgebio.com",
              "848-KYN-928",
              8,
              function (form) {
                MktoForms2.whenRendered(function (form) {
                  console.log(form);
                  let formElement = form.getFormElem()[0];
                  let resizeTimeout;

                  function onResize() {
                    // Clear the previous timeout if it exists
                    if (resizeTimeout) {
                      clearTimeout(resizeTimeout);
                    }
                    // Set a new timeout to delay the execution
                    resizeTimeout = setTimeout(() => {
                      Array.from(formElement.querySelectorAll("[style]"))
                        .concat(formElement)
                        .forEach((element) => {
                          element.removeAttribute("style");
                        });
                    }, 100); // Delay of 100 milliseconds
                  }
                  // Add the event listener for the resize event
                  window.addEventListener("resize", onResize);
                  // Initial call to set content based on initial size
                  onResize();
                });
                MktoForms2.whenReady(function (form) {
                  form.onSuccess(function (values, followUpUrl) {
                    // Custom onFormSubmitted code
                    let pageCenter = document.querySelector(".content-form");

                    pageCenter.classList.add("form-thank-you");

                    if (pageCenter) {
                      pageCenter.scrollIntoView({
                        behavior: "smooth",
                        block: "center",
                      });
                    }
                    return false;
                  });
                });
              }
            );
          </script>
        </div>
      </div>

      <div class="footer-bottom-container">
        <div class="footer-top">
          <p class="form-container__phrase">
            Follow us on LinkedIn, Twitter, Facebook, and YouTube for the latest
            news.
          </p>
          <a
            href="https://www.linkedin.com/company/bridgebio"
            target="_blank"
            class="form-container__social-link"
          >
            <svg
              width="32"
              height="32"
              viewBox="0 0 32 32"
              fill="none"
              xmlns="http://www.w3.org/2000/svg"
            >
              <g id="linkedin">
                <path
                  id="Vector"
                  d="M24.3333 29.3297H7.66667C6.341 29.3284 5.07013 28.8013 4.13274 27.864C3.19534 26.9268 2.668 25.6559 2.66667 24.3304V7.66606C2.668 6.34057 3.19534 5.06974 4.13274 4.13247C5.07013 3.19521 6.341 2.66807 7.66667 2.66675H24.3333C25.659 2.66807 26.9299 3.19521 27.8673 4.13247C28.8047 5.06974 29.332 6.34057 29.3333 7.66606V24.3304C29.332 25.6559 28.8047 26.9268 27.8673 27.864C26.9299 28.8013 25.659 29.3284 24.3333 29.3297ZM19.5392 15.9149C21.6017 15.9149 21.6018 17.8688 21.6018 19.2953V25.5094H25.5626V18.4979C25.5626 16.464 25.2943 15.1309 24.6918 14.1743C23.9502 12.997 22.6808 12.4246 20.8124 12.4246C20.0597 12.3996 19.3141 12.5779 18.6542 12.9409C17.9943 13.3038 17.4444 13.8378 17.0624 14.4868H17.0067V12.7487H13.205V25.5128H17.165V19.192C17.1666 17.573 17.4451 15.9149 19.5392 15.9149ZM6.74992 12.7487V25.5128H10.7152V12.7487H6.74992ZM8.7299 6.39373C8.27257 6.39159 7.82483 6.52538 7.44369 6.77811C7.06255 7.03084 6.76516 7.39111 6.5892 7.81318C6.41323 8.23525 6.36698 8.70008 6.45573 9.14866C6.54449 9.59724 6.76421 10.0093 7.08765 10.3326C7.4111 10.6559 7.82347 10.8758 8.27214 10.9644C8.72081 11.053 9.18593 11.0062 9.608 10.8301C10.0301 10.654 10.3901 10.3565 10.6427 9.97534C10.8954 9.59416 11.0292 9.14652 11.0269 8.68925C11.0266 8.08079 10.785 7.49725 10.3551 7.06661C9.92515 6.63597 9.3417 6.39339 8.73316 6.39207L8.7299 6.39373Z"
                  fill="black"
                />
              </g>
            </svg>
          </a>
          <a
            href="https://twitter.com/BridgeBioPharma"
            target="_blank"
            class="form-container__social-link"
          >
            <svg
              width="32"
              height="32"
              viewBox="0 0 32 32"
              fill="none"
              xmlns="http://www.w3.org/2000/svg"
            >
              <g id="x">
                <path
                  id="Vector"
                  d="M24.3333 29.3297H7.66667C6.341 29.3284 5.07013 28.8013 4.13274 27.864C3.19534 26.9268 2.668 25.6559 2.66667 24.3304V7.66606C2.668 6.34057 3.19534 5.06974 4.13274 4.13247C5.07013 3.19521 6.341 2.66807 7.66667 2.66675H24.3333C25.659 2.66807 26.9299 3.19521 27.8673 4.13247C28.8047 5.06974 29.332 6.34057 29.3333 7.66606V24.3304C29.332 25.6559 28.8047 26.9268 27.8673 27.864C26.9299 28.8013 25.659 29.3284 24.3333 29.3297ZM14.8257 17.9363L19.3683 24.5462H24.3333L17.5833 14.7276L23.7869 7.51691H22.3167L16.931 13.7769L12.6268 7.51691H7.66667L14.1742 16.9848L7.66667 24.5462H9.13681L14.8257 17.9363ZM22.3208 23.4914H20.0625L15.5715 17.0689L14.9132 16.1257L9.6674 8.62676H11.9257L16.1591 14.6801L16.8175 15.6233L22.3176 23.493L22.3208 23.4914Z"
                  fill="black"
                />
              </g>
            </svg>
          </a>
          <a
            href="https://www.facebook.com/profile.php?id=61561087329761"
            target="_blank"
            class="form-container__social-link"
          >
            <svg
              width="32"
              height="32"
              viewBox="0 0 32 32"
              fill="none"
              xmlns="http://www.w3.org/2000/svg"
            >
              <g id="facebook">
                <path
                  id="Vector"
                  d="M22.095 29.3534C19.4 29.3534 15.9527 29.3468 12.9369 29.3401H11.1282C8.93901 29.3351 7.04516 29.3309 6.13265 29.3309C5.59766 29.3309 5.52602 29.3309 5.52352 29.3309C4.76602 29.3301 4.03964 29.0287 3.50407 28.4931C2.96851 27.9574 2.66733 27.2312 2.66667 26.4738V5.52335C2.66733 4.76595 2.96851 4.03975 3.50407 3.50411C4.03964 2.96846 4.76602 2.66714 5.52352 2.66626H26.4757C27.2333 2.66692 27.9598 2.96816 28.4955 3.50383C29.0313 4.03949 29.3327 4.76581 29.3333 5.52335V26.473C29.3327 27.2305 29.0313 27.9569 28.4955 28.4925C27.9598 29.0282 27.2333 29.3294 26.4757 29.3301C26.4165 29.3459 24.9808 29.3534 22.095 29.3534ZM10.4283 13.9105V17.6775H13.7376V26.7838H17.8115V17.6784H20.8482L21.4268 13.9114H17.8123V11.4667C17.7896 10.9593 17.9512 10.4608 18.2669 10.0628C18.4813 9.84172 18.7417 9.67061 19.0298 9.5616C19.3178 9.45258 19.6264 9.40833 19.9335 9.43199H21.5766V6.22409C20.6118 6.06851 19.637 5.98358 18.6599 5.96997C18.0062 5.93934 17.353 6.03949 16.7385 6.26455C16.1241 6.48961 15.5608 6.83505 15.0816 7.28062C14.6195 7.78711 14.2627 8.38034 14.0318 9.02586C13.8009 9.67138 13.7008 10.3563 13.7368 11.0409V13.9147L10.4283 13.9105Z"
                  fill="black"
                />
              </g>
            </svg>
          </a>
          <a
            href="https://www.youtube.com/@BridgeBioPharma-u2b"
            target="_blank"
            class="form-container__social-link"
          >
            <svg
              width="32"
              height="32"
              viewBox="0 0 32 32"
              fill="none"
              xmlns="http://www.w3.org/2000/svg"
            >
              <g id="youtube">
                <g id="Subtract">
                  <path
                    d="M19.4085 15.3332L13.8662 12.1908V18.4755L19.4085 15.3332Z"
                    fill="black"
                  />
                  <path
                    fill-rule="evenodd"
                    clip-rule="evenodd"
                    d="M5.33317 2.6665C3.86041 2.6665 2.6665 3.86041 2.6665 5.33317V26.6665C2.6665 28.1393 3.86041 29.3332 5.33317 29.3332H26.6665C28.1393 29.3332 29.3332 28.1393 29.3332 26.6665V5.33317C29.3332 3.86041 28.1393 2.6665 26.6665 2.6665H5.33317ZM24.3361 8.43791C25.2546 8.67936 25.9763 9.3882 26.2222 10.2902H26.2204C26.6665 11.9235 26.6665 15.3332 26.6665 15.3332C26.6665 15.3332 26.6665 18.7429 26.2204 20.3761C25.9746 21.2781 25.2528 21.987 24.3344 22.2284C22.6713 22.6665 15.9998 22.6665 15.9998 22.6665C15.9998 22.6665 9.32834 22.6665 7.6653 22.2284C6.74685 21.987 6.02508 21.2781 5.77922 20.3761C5.33317 18.7429 5.33317 15.3332 5.33317 15.3332C5.33317 15.3332 5.33317 11.9235 5.77922 10.2902C6.02508 9.3882 6.74685 8.67936 7.6653 8.43791C9.32834 7.99984 15.9998 7.99984 15.9998 7.99984C15.9998 7.99984 22.6713 7.99984 24.3361 8.43791Z"
                    fill="black"
                  />
                </g>
              </g>
            </svg>
          </a>
        </div>

        <div class="footer__contact">
          <p class="bold">
            &copy; 2024 BridgeBio Inc. All rights reserved. |
            <a href="https://investor.bridgebio.com/" target="_blank"
              >For Investors</a
            >
            | <a href="../../careers/index.html">careers</a> |
            <a href="../../terms-of-use/index.html">terms of use</a> |
            <a href="../../bridgebio-global-privacy-policy/index.html"
              >privacy policy</a
            >
            |
            <a href="../../cookies-notice/index.html">cookies&nbsp;notice</a> |
            <a href="../../us-expanded-access-policy/index.html"
              >us&nbsp;expanded&nbsp;access&nbsp;policy</a
            >
            | <a href="../../contact-us/index.html">contact us</a> |
            <a href="../../sms-policy/index.html">sms&nbsp;policy</a> |
            <a href="../../social-policy.html">social policy</a>
          </p>
          <p>
            3160 Porter Drive, Suite 250, Palo Alto, CA, 94304 | 650-391-9740 |
            <a
              href="../../cdn-cgi/l/email-protection.html#5c35323a331c3e2e35383b393e3533723f3331"
              ><span
                class="__cf_email__"
                data-cfemail="41282f272e0123332825262423282e6f222e2c"
                >[email&#160;protected]</span
              ></a
            >
            | MAT-AS—0001
          </p>
        </div>
      </div>
    </footer>

    <script
      data-cfasync="false"
      src="../../cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"
    ></script>
  </body>
</html>
